These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 18446147)

  • 1. New concepts of resistance in the treatment of Helicobacter pylori infections.
    Graham DY; Shiotani A
    Nat Clin Pract Gastroenterol Hepatol; 2008 Jun; 5(6):321-31. PubMed ID: 18446147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial.
    Zhou L; Zhang J; Song Z; He L; Li Y; Qian J; Bai P; Xue Y; Wang Y; Lin S
    Helicobacter; 2016 Apr; 21(2):91-9. PubMed ID: 26104022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
    Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP
    Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of real-time PCR-based detection of Helicobacter pylori infection and genotypic resistance-guided quadruple therapy as the first-line treatment for functional dyspepsia with Helicobacter pylori infection.
    Liu Q; Qi D; Kang J; Jin Y; Liu W; Gao W; Hou P; Lu J
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):221-5. PubMed ID: 25629566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel and Effective Therapeutic Regimens for
    Hu Y; Zhu Y; Lu NH
    Front Cell Infect Microbiol; 2017; 7():168. PubMed ID: 28529929
    [No Abstract]   [Full Text] [Related]  

  • 6. Helicobacter pylori antimicrobial resistance during a 5-year period (2013-2017) in northern Spain and its relationship with the eradication therapies.
    Cosme A; Torrente Iranzo S; Montes Ros M; Fernández-Reyes Silvestre M; Alonso Galán H; Lizasoain J; Bujanda L
    Helicobacter; 2019 Feb; 24(1):e12557. PubMed ID: 30460730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for
    Bang CS; Lim H; Jeong HM; Shin WG; Choi JH; Soh JS; Kang HS; Yang YJ; Hong JT; Shin SP; Suk KT; Lee JJ; Baik GH; Kim DJ
    Gut Microbes; 2020 Sep; 11(5):1314-1323. PubMed ID: 32362221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
    Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and future insights in H. pylori eradication regimens: the need of tailoring therapy.
    Papastergiou V; Georgopoulos SD; Karatapanis S
    Curr Pharm Des; 2014; 20(28):4521-32. PubMed ID: 24180408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study.
    Liang X; Xu X; Zheng Q; Zhang W; Sun Q; Liu W; Xiao S; Lu H
    Clin Gastroenterol Hepatol; 2013 Jul; 11(7):802-7.e1. PubMed ID: 23376004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility-guided therapy for Helicobacter pylori-infected penicillin-allergic patients: A prospective clinical trial of first-line and rescue therapies.
    Luo L; Huang Y; Liang X; Ji Y; Yu L; Lu H
    Helicobacter; 2020 Aug; 25(4):e12699. PubMed ID: 32428369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial.
    Macías-García F; Bastón-Rey I; de la Iglesia-García D; Calviño-Suárez C; Nieto-García L; Domínguez-Muñoz JE
    Helicobacter; 2019 Feb; 24(1):e12546. PubMed ID: 30346636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failed Eradication for Helicobacter pylori. What Should Be Done?
    Mégraud F
    Dig Dis; 2016; 34(5):505-9. PubMed ID: 27332826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond.
    Graham DY; Lu H; Yamaoka Y
    Drugs; 2008; 68(6):725-36. PubMed ID: 18416582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Helicobacter pylori infection: Where are we now?
    Liou JM; Wu MS; Lin JT
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1918-1926. PubMed ID: 27088632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
    Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
    Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence-based recommendations for successful Helicobacter pylori treatment.
    Wu JY; Liou JM; Graham DY
    Expert Rev Gastroenterol Hepatol; 2014 Jan; 8(1):21-8. PubMed ID: 24410470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward population specific and personalized treatment of Helicobacter pylori infection.
    Liou JM; Chen PY; Kuo YT; Wu MS;
    J Biomed Sci; 2018 Oct; 25(1):70. PubMed ID: 30285834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal.
    Miftahussurur M; Shrestha PK; Subsomwong P; Sharma RP; Yamaoka Y
    BMC Microbiol; 2016 Nov; 16(1):256. PubMed ID: 27809767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
    Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.